Scotiabank has highlighted three biotechnology companies as its "top picks," each with the potential to more than double in stock price over the next 12 months. The bank's optimism for these companies and the broader biotechnology sector is partly based on anticipated changes in the macroeconomic environment.
line Liquidia Corp Scotiabank is optimistic about the company's Yutrepia treatment for pulmonary arterial hypertension, set to launch in May 2025. Despite entering a competitive market, the bank believes, Yutrepia could differentiate itself on superior treatment results.
line Ocular Therapeutix The bank sees Ocular's Axpaxli treatment for wet age-related macular degeneration as a potential gamechanger. wAMD is a common condition that affects vision — making reading and recognizing faces difficult — for people in their 50s and 60s, according to the U.K.'s National Health Service.
line